Keywords: Kyowa Hakko Kirin, Poteligeo, ATL, Japan, Minirinmelt, Nocturnal enuresis, Ferring Pharma
Kyowa Hakko debuts Poteligeo in Japan; co-promotes Minirinmelt with Ferring
Article | 29 May 2012
Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has launched Poteligeo (mogamulizumab) injection, a therapeutic antibody for patients with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
